(5)
🔬 Not a moonshot. A methodical build. (10)(11)(12)(13)
What gives this edge credibility is that Urcosimod has already delivered.
In 2023, OKYO completed a 240-patient Phase 2 trial
for dry eye disease (DED) — a massive global market with tens of millions of patients and multiple blockbuster medications.
Urcosimod didn’t just squeak by. It hit targets that others routinely miss:
- Significant improvement in eye surface damage by Day 29
- Pain relief by Day 15
- Improved vision symptoms by the end of the trial
- Safety on par with placebo —
no steroids, no opioids, no serious events
Dry eye trials are notoriously tricky. Many fail to show both sign relief and symptom improvement.
OKYO’s trial showed both, in its very first human study.
That’s why insiders doubled down.
That’s why the FDA gave them a green light to go faster.
That’s why attention is now shifting
to what comes next.
🔍 Undervalued and underexposed … for now (9)
Here’s what makes this moment unusual:
Despite clinical success, regulatory traction, and a pipeline built on firsts, OKYO is still trading at a market cap of ~$70 million.
Compare that to:
- Dry eye peers like
Aldeyra (~$150M–$160M), also in mid-to-late stage
- Recent takeouts like Aerie Pharmaceuticals (~$770M)
- Or Xiidra — the poster child — at over $5B
The mismatch is clear.
The reason? Timing.
OKYO Pharma Limited (Nasdaq:OKYO) hasn’t hit its next data drop yet.
And once it does, that number likely won’t stay low.
This kind of gap — where the clinical progress
is ahead of the market reaction — rarely lasts.
📆 The next inflection point is already scheduled
OKYO’s NCP trial is ongoing now.
The design is tight. The endpoints are clear.
The science has support.
Top-line data is expected in Q4 2025.
That will be the defining moment — not just for OKYO, but for the field itself.
If the results are
strong?
- OKYO becomes the only company with a clinically validated treatment for NCP
- Conversations about licensing, partnerships, or strategic combinations start becoming real
- The market reassesses everything — and fast
Remember: Urcosimod already showed signs of pain reduction in dry eye patients.
This isn’t a wild leap. It’s a logical
extension.
And the mechanism is built for it.
🧠 Most won’t realize what they missed… until it’s obvious
Every cycle has a few companies like this.
The ones that made big strides quietly.
That stayed small while building real traction.
That were ahead of the narrative — and had data to back it up.
By the time headlines hit, the price
changes. The game changes.
Right now, OKYO is:
✅ First to trial in a wide-open disease space
✅ Backed by strong dry eye data
✅ Aligned internally — from insiders to creditors
✅ On-track to deliver a potential first-ever solution in NCP
✅ Operating with a valuation that doesn’t reflect what’s been built
The match is lit.
And the fuse is burning.
🔍 You’ve seen this pattern
before 🔷
Small team. Big science. Low market cap. Real data. Upcoming catalyst.
It’s never about waiting for confirmation — by the time everyone agrees, the move is over.
Right now, you’re early.
But not for long.
The data clock is ticking. The market is watching.
And in the months ahead, everything will get louder.
🟢 Check out OKYO
Pharma Limited (Nasdaq:OKYO) Now!
To your success,
Max Masters
Co-founder, Market Tips Newsletter
Sources:
1. https://finance.yahoo.com/quote/OKYO/
2. https://finance.yahoo.com/quote/OKYO/key-statistics/
3.
https://finance.yahoo.com/quote/OKYO/history/
4. https://okyopharma.com/
5. https://okyopharma.com/wp-content/uploads/2024/07/OKYO-Slide-Deck-for-July.pdf
6. https://okyopharma.com/wp-content/uploads/2025/02/OKYO-FEB-25-Phase-2a-Trial-in-NCP-to-Complete-Enrollment-in-2Q25-Reiter.pdf
7. https://bit.ly/45jdShe
8. https://www.ophthalmologymanagement.com/news/2025/okyo-pharma-to-complete-enrollment-of-neuropathic-corneal-pain-trial-by-end-of-q2/
9. https://www.biopharmadive.com/news/aerie-pharmaceuticals-alcon-deal-glaucoma/630267/
10. https://okyopharma.com/wp-content/uploads/2023/09/OKYO_Enrollment-PR_FINAL_GJ.pdf
11.
https://okyopharma.com/technology/
12. https://glance.eyesoneyecare.com/stories/2025-05-05/fda-grants-fast-track-designation-to-okyo-pharma-s-ncp-therapeutic/
13. https://glance.eyesoneyecare.com/stories/2025-04-02/okyo-s-urcosimod-demonstrates-long-term-stability-for-ncp/
14. https://bit.ly/3FI1jSd
15.
https://finance.yahoo.com/news/okyo-pharma-present-bio-international-123000318.html
